Share on

Global Cardiovascular Drugs Market Size, Share, Trends, COVID-19 impact & Growth Analysis Report – Segmented By Drugs Type, Disease indication, End-Users & Region – Industry Forecast (2023 to 2028).

Published: March, 2023
ID: 12157
Pages: 200
Formats: report pdf report excel report power bi report ppt

Global Cardiovascular Drugs Market Size (2023 to 2028)

The global cardiovascular drugs market is estimated to grow at a CAGR of 5.96% from 2023 to 2028. The market was valued at USD 99.15 billion in 2023 and is predicted to be worth USD 132.44 billion by 2028.

Cardiovascular Drugs Market Share Insights:

  • Based on the Drug type, the anticoagulants segment had the largest market share of the global cardiovascular drugs market in 2022.
  • The North American cardiovascular drugs market dominated the market in 2022.
  • The Asia-Pacific cardiovascular drugs market is anticipated to grow at a CAGR of 7.88% from 2023 to 2028.
  • The European cardiovascular drugs market is estimated to grow significantly during the forecast period.

The increasing popularity of these drugs for the rapid relief of several ailments will offer immense growth to the global cardiovascular drugs market during the forecast period. In addition, these drugs contain blood thinners such as warfarin and heparin, anti-arrhythmic drugs such as Digitalis, and blood pressure regulators such as amlodipine, nifedipine, etc.

COVID-19 Impact on the global cardiovascular drugs market:

Major pharmaceuticals, biotechnology companies, and governments worldwide are working to limit the COVID-19 pandemic, from supporting vaccine development to planning for challenges in the drug supply chain. The pharmaceutical industry is currently developing medicine to tackle the virus and its complications. In addition, commonly used drugs, such as hydroxychloroquine, have seen a dramatic increase in demand for the treatment of COVID-19. This major shift in the field of R&D has seen a significant impact on the cardiovascular drugs market. As a result, COVID-19 has decreased supply and market demand. At the same time, many people have stocked on cardiovascular drugs due to panic and fear of a shortage of drugs. Furthermore, the pharmaceutical and biotechnology industry is expected to experience significant growth due to the demand for vaccines and drugs to treat COVID-19.


As the world population exceeds 7 billion, more people reach old age, and cardiovascular disease deaths are rising. Cardiovascular diseases are one of the leading causes of death across the world. According to the American Heart Association, in 2015, approximately 45% of the American population suffered from some form of cardiovascular disease; In addition, this prevalence is expected to reach 45% by 2035. For this reason, efforts to prevent and treat cardiovascular disease through drugs are rising, resulting in slower death rates and expanding the cardiovascular drug market. Additionally, the increasing number of diabetic patients has immense potential for the growth of the cardiovascular drugs market. Other factors include increased smoking, unhealthy diets and obesity, a sedentary lifestyle, and harmful use of alcohol, leading to cardiovascular disease and medication.

The increase in sedentary and busy lifestyles, stressful jobs, and changing consumer preferences for drugs drives the cardiovascular drug market, especially for chronic diseases such as cancer, diabetes, and cardiovascular disease. 

According to the World Health Organization, the prevalence of chronic diseases is expected to increase by 64% worldwide by 2025. These factors are expected to increase the patient pool globally, thus boosting the cardiovascular drugs market during the forecast period. In addition, increasing R&D spending for new cardiovascular drugs and increasing government initiatives to increase vigilance for different cardiovascular diseases are expected to drive further market growth.

In addition, several ongoing research activities of major players to develop technologically advanced cardiovascular drugs with reduced side effects, such as biosimilarsmonoclonal antibodies, and peptide therapeutics to meet patient needs, are expected to further expand the cardiovascular drugs market during the forecast period. In addition, increasing rapid product launches significantly impact the cardiovascular drugs market. Moreover, favorable reimbursement policies and an awareness of the seriousness of cardiovascular diseases are further estimated to favor the market during the forecast period.


Certain factors, namely strict regulations and side effects associated with cardiovascular drugs hamper the growth of the cardiovascular drug market. In addition, the expiration of patents for several highly effective drugs is also restraining the development of the cardiovascular drug market. On the other hand, the high costs associated with drugs significantly affect the market growth rate. Furthermore, the prices are unaffordable for people in developing economies having negligible reimbursement policies. As a result, the market in developing countries fails to provide for the unmet market needs.




Market Size Available

2022 to 2028

Base Year


Forecast Period

2023 to 2028

Segments Covered

Segmented By Drugs Type, Disease Indication, End-Users & Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

This research report on the global cardiovascular drugs market has been segmented and sub-segmented based on drug type, disease indication, end-users, and region.

Global Cardiovascular Drugs Market – By Drug Type:

  • Antihypertensive
  • Antihyperlipidemic
  • Anticoagulants
  • Antiplatelet Drugs
  • Others

Based on the drug type, the anticoagulants segment is expected to expand rapidly due to their status as relatively expensive medicines that provide critical life-saving functions. All of these drugs are among the most often prescribed in the world.

Global Cardiovascular Drugs Market – By Disease Indication:

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Arrhythmia
  • Others

The hypertension segment is expected to increase at a rapid CAGR than the other disease indications. This is because different types of medicines are being used more frequently as the frequency of further CVD rises.

Global Cardiovascular Drugs Market – By End-Users:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

The hospital pharmacy segment is projected to have the largest share since these drugs are usually provided following a complete diagnosis, typically performed at these institutions. The category of retail pharmacies is expected to come in second. The online pharmacy industry is projected to expand fastest due to its increasing usage.

Global Cardiovascular Drugs Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Geographically, The APAC cardiovascular drugs market dominated the global market, accounting for 42% in 2021. The dominance of the APAC region can be attributed to many companies building their R&D facilities in the region; low wages and the availability of skilled labor encourage manufacturing companies to invest in Asia. Moreover, increased awareness and favorable healthcare initiatives will support the growth of the cardiovascular drugs market in the region. As a result, the APAC region's fastest-growing cardiovascular drug markets will be seen in Japan, China, and India.

The North American cardiovascular drugs market was the second-largest region, with 28% of the global market. At the same time, Europe was third, followed by the MEA region. North America is expected to dominate the global cardiovascular drugs market during the forecast period. This is due to an increased awareness of various heart diseases in the region. The United States is expected to have the highest market share for cardiovascular drugs, followed by Canada in North America. According to the United States CDC, high blood pressure, high lipid profile, and smoking are key risk factors for many cardiovascular diseases. About half of the American population (47%) has at least one of these three risk factors. The CDC also estimates that a person in the United States dies every second from cardiovascular disease. These alarming statistics raise concerns about the need to control the threat. Thus, these aspects constitute a red carpet of growth for the North American cardiovascular drug market.

The Europe cardiovascular drugs market is expected to showcase a CAGR of 5.15% from 2022 to 2027. Germany, the UK, Spain, Italy, and France hold a significant share of the cardiovascular drugs market. The growing aging population, the increasing prevalence of cardiovascular disease, the high incidence of obesity, and an unhealthy lifestyle drive the demand for the European cardiovascular drugs market.

The Latin American cardiovascular drugs market is expected to value at USD 10.15 billion by 2027.

The cardiovascular drugs market in MEA was the smallest region in the global market in 2021. However, it is likely that the initiatives of local governments to achieve self-sufficiency in the manufacture of pharmaceuticals and the incentives to produce generics in countries like Brazil, South Africa, Saudi Arabia, etc., stimulate market growth in the Middle East and Africa.


Merck & Co, Sanofi S.A., Pfizer Inc., Bristol-Myers Squibb Company, and Novartis AG are some companies operating in the global cardiovascular drugs market.


  • In January 2019, an Indian company, Natco Pharma, announced the launch of the generic version of valsartan-sacubitril, a cardiovascular medicine for treating congestive heart failure. Novartis AG holds the Indian patent for valsartan-sacubitril called Vymada. Launching the newer drug will create better growth opportunities for the cardiovascular drugs market.
  • In February 2019, Novartis AG and Blackstone's Life Sciences announced the launch of Anthos Therapeutics for cardiovascular drug development, as there is a significant unmet need for next-generation antithrombotic therapies in patients.
  • In April 2019, Sanofi launched the new cardiovascular drug Praluent to treat hyperlipidemia.
  • In May 2019, Pfizer Inc. received US FDA approval for their oral administration drugs, namely VYNDAQEL and VYNDAMAX.
  • In February 2020, Recent developments in cardiovascular biologics, such as the PCSK9 inhibitor from Pfizer and the new anti-LDL drug from Esperion Therapeutics ETC-1002.

Please wait. . . . Your request is being processed


How big is the global cardiovascular drugs market?

As per our research report, the global cardiovascular drugs market size is forecasted to be worth USD 132.44 billion by 2028.

At What CAGR, the global cardiovascular drugs market is expected to grow from 2023 to 2028?

From 2023 to 2028, the global market for cardiovascular drugs market is estimated to be growing at a CAGR of 5.96%.

Which segment by disease indication led the cardiovascular drugs market in 2022?

Based on disease indication, the hypertension segment dominated the cardiovascular drugs market in 2022.

Which are the leading players in the cardiovascular drugs market?

Companies playing a major role in the global cardiovascular drugs market are Merck & Co, Sanofi S.A., Pfizer Inc., Bristol-Myers Squibb Company, and Novartis AG.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample